Gilead to Launch Generic Versions of Its Hepatitis Drugs

By Reuters Staff

(Reuters) - Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

The drugmaker's generic version of drugs such as Harvoni (a combination of ledipasvir and sofosbuvir) and Epclusa (sofosbuvir-velpatasvir), which raked in combined sales of $831 million in the quarter ended June 30, will be launched via a newly created subsidiary Asegua Therapeutics LLC.

Gilead said the low-cost variants of the drugs will be available at a list price of $24,000 for the most common course of therapy from January.

U.S. healthcare companies, ranging from insurers to drug retailers, are stepping up efforts to combat rising drug prices that have been widely criticized by regulators.

Pharmacy benefits manager Express Scripts Holding Co said Gilead's move "is a step in the right direction."

(c) Copyright Thomson Reuters 2018. Click For Restrictions - https://agency.reuters.com/en/copyright.html

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here